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Abstract objective The HPTN 071 (PopART) trial is examining the impact of a package including universal
testing and treatment on community-level HIV incidence in Zambia and South Africa. We conducted
a nested case–control study to examine factors associated with acceptance of home-based HIV testing
and counselling (HB-HTC) delivered by community HIV-care providers (CHiPs) in PopART
intervention communities.
methods Of 295 447 individuals who were offered testing, random samples of individuals who
declined HB-HTC (cases) and accepted HB-HTC (controls), stratified by gender and community,
were selected. Odds ratios comparing cases and controls were estimated using multivariable logistic
regression.
results Data from 642 participants (313 cases, 329 controls) were analysed. There were no
differences between cases and controls by demographic or behavioural characteristics including age,
marital or socio-economic position. Participants who felt they could be open with CHiPs (AOR:
0.46, 95% CI: 0.30–0.71, P < 0.001); self-reported as not previously tested (AOR: 0.64; 95% CI:
0.43–0.95, P = 0.03); considered HTC at home to be convenient (AOR: 0.38, 95% CI: 0.27–0.54,
P = 0.001); knowing others who had accepted HB-HTC from the CHiPs (AOR: 0.49, 95% CI: 0.31–
0.77, P = 0.002); or were motivated to get treatment without delay (AOR: 0.60, 95% CI: 0.43–0.85,
P = 0.004) were less likely to decline the offer of HB-HCT. Those who self-reported high-risk sexual
behaviour were also less likely to decline HB-HCT (AOR: 0.61, 95% CI: 0.39–0.93, P = 0.02).
Having stigmatising attitudes about HB-HTC was not an important barrier to HB-HCT uptake. Men
who reported fear of HIV were more likely to decline HB-HCT (AOR: 2.68, 95% CI: 1.33–5.38,
P = 0.005).
conclusion Acceptance of HB-HTC was associated with lack of previous HIV testing, positive
attitudes about HIV services/treatment and perception of high sexual risk. Uptake of HB-HCT among
those offered it was similar across a range of demographic and behavioural subgroups suggesting it
was ‘universally’ acceptable.
keywords home-based HIV testing, universal test and treat, case–control study, sub-Saharan Africa
Introduction
Great advances have been made in controlling the HIV
epidemic over time and especially so in the last decade.
HIV incidence worldwide has declined, as have
HIV-related deaths [1]. The number of people receiving
antiretroviral treatment (ART) has increased to 17
million and coverage has reached unprecedented levels
even in high-prevalence countries [2]. To gain further
ground, a fast-track strategy is called for to achieve
UNAIDS’ 90-90-90 targets – with benefits for individual
health and prevention of transmission [1, 3–7]. The
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feasibility of treatment as prevention for public health
benefit, whereby a sufficiently high proportion of those
infected with HIV know their status, start ART and
become virally suppressed so that transmission and HIV
incidence may be reduced to a very low level, is currently
being tested by a number of studies [8–11]. The HPTN
071/ Population Effects of Antiretroviral Therapy to
Reduce HIV Transmission (PopART) trial is being con-
ducted in 21 communities in Zambia and South Africa
(with an average population of >50 000 individuals/com-
munity) to examine the impact of universal testing and
treatment (UTT) on community-level HIV incidence [9,
12.]
Despite the progress so far, unless uptake of testing is
extensive and inclusive in terms of acceptability to all
subsets of the population, the full potential of UTT will
not be realised. Home-based HIV testing and counselling
(HB-HTC) has the potential to increase awareness of
HIV status in previously undiagnosed individuals in sub-
Saharan Africa [13–16]. The PopART intervention
includes door-to-door HB-HTC with the aim of achieving
universal testing. A case–control (CC) study on a ran-
domly selected subset of those who had accepted
(controls) and those who had declined HB-HTC (cases)
when offered by Community HIV-care Providers (CHiPs)
was carried out, to examine the acceptability of the
PopART HB-HTC intervention during the first year of
delivery. In addition to exploring demographic, lifestyle,
health and behavioural characteristics, we explored dif-
ferences in perceptions between cases and controls about
factors that may affect uptake of HB-HTC. We examined
participants’ perceptions of HIV services, advantages and
disadvantages of accepting HB-HTC for them as individ-
uals and enquired about stigmatising attitudes which may
affect uptake. By comparing non-acceptors (cases) and
acceptors (controls) of HB-HTC, we hoped to identify
any differences and any excluded subsets of the popula-
tion so that recommendations could be made to help
enable universal knowledge of HIV status be achieved
through HB-HTC.
Methods
The design of the HPTN 071 (PopART) trial has been
described previously [9]. Key elements of the trial are
shown in Figure 1. Working in pairs, the CHiPs (who
3-arm cluster-randomised  trial with 21 communities 
Full PopART
intervention 
including
immediate ART 
irrespective of CD4 
count
Standard of care at 
current service 
provision levels 
including 
ART initiation 
according to current 
national guidelines
ART initiation 
according to current 
national guidelines
Seven communities 
per arm (N = 21)Arm A Arm B Arm C
PopART intervention 
except
PopART intervention package
Annual rounds of  Home-Based Voluntary HIV Testing by Community HIV-care Providers (CHiPs)
Health promotion, Active Referral and/or Retention in Care support by CHiPs for the following:
• Voluntary Medical Male Circumcision (VMMC) for HIV-negative men
• Prevention of Mother to Child Transmission (PMCT) for HIV-positive women
• HIV treatment and care for all HIV-positive individuals
• Promotion of sexual health and TB services
• Condom provision
ART irrespective of CD4 count or immune status provided at the local health centre in Arm A 
~ 2000 random sample 
from each community :
Population Cohort 
N = 42 000
Primary outcome:
HIV incidence at 36 months
12 in Zambia
9 in S. Africa
Figure 1 PopART trial schema.
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were community members employed to work in their
communities) were assigned to zones with approxi-
mately 500 households to which they delivered the
intervention, including HB-HCT. During the first year
of the PopART intervention, 194 795 individuals in
Zambia (88 860 men/105 935 women) and 100 652 in
South Africa (44 172 men/56 480 women) were offered
HB-HTC by CHiPs in the 14 intervention communities.
Of these, 126 208 individuals in Zambia (55 568 men/
70 640 women) and 92 375 (40 519 men/51 856
women) in South Africa accepted testing. Individuals
who self-reported HIV-positive status were not routinely
offered testing (and are not included in the above
figures).
The nested case–control study was carried out in all
the intervention (Arms A and B) communities – eight in
Zambia and six in South Africa. The study objectives
were to identify differences between non-acceptors (cases)
and acceptors (controls) of HB-HTC in the first annual
round of HB-HTC in PopART and to identify reasons for
non-acceptance of HB-HTC.
While delivering the PopART intervention, CHiPs cap-
tured the details of all individuals who consented to the
intervention offered by CHiPs, irrespective of whether or
not they accepted HB-HTC, on an electronic register [9].
From the electronic register which recorded uptake of test-
ing, random samples of non-acceptors (cases) and accep-
tors (controls) of HB-HTC were selected, with a ratio of 1
case:1 control, an equal number of men and women, and
an equal number from each community, to have adequate
representation of individuals from all the PopART inter-
vention communities and from both genders. It was impor-
tant to frequency match by gender so that we could ensure
we had an adequate sample of men who are often under-
represented in studies of HIV test uptake. An initial ran-
dom sample in excess of the number needed to be recruited
was selected, in anticipation of difficulties in finding partic-
ipants – due to mobility of community members with fre-
quent change in address.
To be eligible for the case–control study, participants
had to be ≥18 years old, able and willing to provide
informed consent and have participated in the first year of
the PopART intervention. Belonging to the population
cohort of the PopART trial (the research cohort in which
the trial primary outcome will be measured after 3 years of
annual follow-up) (Figure 1), or to a separate PopART
case–control study, was exclusion criteria to avoid research
fatigue among study participants. Already being known to
be HIV-infected at the time of the initial CHiP visit was also
an exclusion criterion as participants who self-reported
HIV-positive status were not offered HB-HTC. HB-HTC
acceptance/non-acceptance was defined based on whether a
community member had accepted/not accepted HB-HTC
offered by CHiPs at the time of random selection in January
(Zambia) andMarch (South Africa) 2015 – representing
one year since the start of the intervention in each country.
Verbal permission to allow research staff to
approach participants was obtained by the CHiP staff
who had provided the intervention to individual com-
munity members. Written informed consent for study
participation was then obtained by study research
assistants (RAs). RAs conducted surveys using stan-
dardised questionnaires administered electronically.
Questionnaire themes were informed by current evi-
dence in the literature or anecdotal local information
on factors that may influence uptake of HIV testing.
RAs were kept unaware of participants’ case or con-
trol status. In the questionnaire, the question about
whether the individual had accepted or declined HB-
HTC was asked at the end of the interview to min-
imise interviewer bias.
While monitoring data as part of routine quality
assurance, the study team uncovered some irregularities
in data collection in South Africa. In-depth internal
and independent investigations followed, with oversight
from the relevant ethical and regulatory bodies respon-
sible for the study. Consequently, data from one com-
munity were not used due to concerns about
substantive data irregularities, while in the remaining
five communities in South Africa, a rigorous data verifi-
cation process was undertaken to ensure data integrity.
Only participants who could be recontacted and whose
data were verified as genuine were retained. The verifi-
cation process involved confirming the identity of the
participant and checking that responses to selected key
questions matched responses given during the initial
CC visit. No irregularities related to this study were
identified in Zambia at any stage.
The final sample size of ~650 participants (1:1 case:-
control ratio) provided ~80% study power to detect asso-
ciations with odds ratios of ~1.75 or higher (or ~0.5 or
lower), for explanatory variables with 15% prevalence
among controls (a = 0.05). The age/sex distribution of
the final study sample was similar to that of the initial
randomly selected sample.
Multivariable logistic regression was used to estimate
odds ratios, including community and gender in all
models to account for the frequency-matched sampling
strategy. Age category was also included as an a priori
potential confounding factor. Additional variables (re-
lated to demographic or behavioural characteristics but
not opinions or perceptions) for which there was at least
weak statistical evidence of association with HB-HTC
acceptance were included as potential confounding
© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 3
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variables. Likelihood ratio tests (LRT) were performed
to assess the statistical evidence for associations. Evi-
dence of effect modification by gender and country was
explored. For variables with three or more response cat-
egories and potential for a dose–response relationship,
test for trends was performed.
The study was approved by the Ethics Committees of
the University of Zambia, Stellenbosch University and the
London School of Hygiene and Tropical Medicine.
Results
As shown in Figure 2a, of 910 non-acceptors of HB-
HCT (cases) randomly selected to be contacted by
CHiPs, 440 (48%) were found and agreed for their
contact information to be passed on to the case–control
field research assistants (RAs). Of them, 380 (86%)
were consented into the study (Figure 2a). In South
Africa, data were verifiable for 73 of the 140 (52%)
cases initially recruited there. There were 313 cases in
the final study sample. The proportions recruited
among potential controls were similar as shown in Fig-
ure 2b with 329 controls in the final sample. Data
from 642 participants were included in the final analy-
sis – 77% (495) from eight communities in Zambia
and 23% (147) from five communities in South Africa
(Table 1).
Demographic and household conditions and lifestyle,
behavioural and health characteristics
Cases and controls were well balanced by trial arm,
community and gender, reflecting the sampling strategy
of the study. Participants were distributed fairly evenly
across age categories with slightly higher proportions in
younger age groups (Table 1). The median age among
cases was 32y (IQR: 23–43) and 30y (IQR: 22–40)
among controls. The majority of cases and controls
were married. While the proportion of participants
with higher education was relatively low (12–13%),
most had had secondary school education. Most partic-
ipants were unemployed.
Cases and controls were similarly distributed across
almost all the characteristics examined. There were no
differences by ethnicity or religion, nor in household con-
ditions, sexual behaviour or health status (including men-
tal health measured by WHO validated Self-Reported
Questionnaire [9], circumcision status and history of
pregnancies) (Table 1 and from data not shown).
However, participants who had lived in the community
for more than 3 years had twice the odds of declining
HB-HCT than those who had been resident for <3 years
(adjusted odds ratio (AOR):2.01,95% confidence interval
(95% CI):1.25–3.22, P = 0.003).
Neither the number of other household members who
were present when HB-HTC was offered to the house-
hold, nor the presence of the participant’s partner, were
associated with acceptance of HB-HCT (Table 1).
Perceptions of HIV services affecting uptake of HB-HTC
As shown in Table 2, most participants did not know
the CHiP prior to the PopART home visit, and there
was no association with uptake of HB-HTC. The
majority had faith in the confidentiality of services
provided by CHiPs, and there was no difference
between cases and controls. However, when asked
about whether they could talk openly to the CHiPs,
participants who ‘strongly agreed’ that they were com-
fortable talking openly to CHiPs (who provided HB-
HTC) were less likely to have declined HB-HTC com-
pared to those who ‘strongly disagreed/disagreed’
(AOR: 0.34, 95% CI: 0.12–0.91, P = 0.03). There is
evidence of a trend suggesting that the more strongly
a participant agreed that they could talk to the CHiP
openly, the less likely they were to have declined HB-
HCT (test for trend P = 0.003). Also, the more
strongly participants agreed that providing treatment
widely could reduce incidence of new infections, the
less likely they were to have declined HB-HCT (test
for trend P = 0.03).
Perceived advantages, disadvantages of HB-HTC
When non-acceptors and acceptors were asked (identical)
standardised questions about factors that encourage HIV
testing (regardless of whether they actually did), further
associations emerged. Individuals who reported never
previously testing for HIV were less likely to have
declined HB-HTC (AOR: 0.64, 95% CI: 0.43–0.95,
P = 0.03). Similarly, those who knew someone who had
had an HIV test with the CHiPs (AOR: 0.49, 95% CI:
0.31–0.77, P = 0.002); thought they could get treatment
without delay if HIV positive (AOR: 0.60, 95% CI:
0.43–0.85, P = 0.004); accepted the CHiP advice that it
was good to have an HIV test (AOR: 0.33, 95% CI:
0.23–0.48, P < 0.001); and considered testing at home as
convenient (AOR: 0.38, 95% CI: 0.27–0.54, P < 0.001)
– were less likely to have declined HB-HTC. Participants
who indicated that their sexual behaviour put them at
risk of HIV (as a reason to test) were also less likely to
have declined HB-HTC (AOR: 0.61, 95% CI: 0.39–0.93,
P = 0.02).
4 © 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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When exploring reasons against accepting HB-HTC,
those who reported confidence in being HIV negative (so
there was no need to test) (AOR: 1.61, 95% CI: 1.04–
2.51, P = 0.03) and reluctance to test again after recent
testing (the definition of recency was not specified and
left to the interpretation of the participant) (AOR: 1.69,
CHiPs attempted contact with 910 non-acceptors of HBT,
randomly selected from CHiP database from the first annual round of HBT in PopART
(Zambia: 560/SA1: 3502)
CHiPs attempt contacted with 910 acceptors of HBT,
randomly selected from CHiP database from the first annual round of HBT in PopART
(Zambia: 560/SA1: 3502)
Usually three attempts made to locate
individual if not initially found
Usually three attempts made to locate
individual if not initially found
Usually three attempts made to locate
individual if not initially found
Usually three attempts made to locate
individual if not initially found
RAs attempted contact with 440 (48%) potential cases to obtain
informed consent to participate in CC study
(Zambia: 272/SA: 168)
RAs attempted contact with 443 (49%) potential controls to obtain
informed consent to participate in CC study
(Zambia: 284/SA: 159)
380 (86%) cases in initial study sample
(Zambia: 240/SA: 140)
391 (88%) controls in initial study sample
(Zambia: 255/SA: 136)
329 (84%) controls in final study sample
(Zambia: 255/SA: 74)
313 (82%) cases in final study sample
(Zambia: 240/SA: 73)
470 individuals could not be located or
declined to be contacted by CC team
(Zambia: 288/SA: 182)
467 individuals could not be located or
declined to be contacted by CC team
(Zambia: 276/SA: 191)
60 individuals could not be located,
declined participation or were ineligilble for the study
(Zambia: 32/SA: 28)
52 individuals could not be located,
declined participation or were ineligilble for the study
(Zambia: 29/SA: 23)
67 not found for data verification or excluded during data
verification process in SA
62 not found for data verification or excluded during data
verification process in SA
SA = Sounth Africa1.
Excludes participants from
the community from
which data had to omitted
2.
SA = Sounth Africa1.
Excludes participants from
the community from
which data had to omitted
2.
(a)
(b)
Figure 2 (a) Case (non-acceptor) selection process and sampling fraction. (b) Control (acceptor) selection process and sampling
fraction.
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Table 1 Demographic and household conditions, and lifestyle, behavioural and health characteristics of cases and controls
Cases
(non-acceptors)
n (%)
Controls
(acceptors)
n (%)
Odds
ratio†
LRT‡ P-value,
95% confidence
interval
Adjusted
odds ratio§
LRT‡ P-value, 95%
confidence
interval
Total 313 329
Gender
Male 153 (49) 150 (46)
Female 160 (51) 179 (54)
Demographic characteristics
Age category Ptrend* 0.57
18–24 years 95 (30) 110 (33) 1 0.16 1 0.34
25–34 years 79 (25) 98 (30) 0.93 0.62–1.14 0.87 0.57–1.32
35–44 years 73 (23) 54 (16) 1.55 0.98–2.45 1.35 0.84–2.15
≥45 years 66 (21) 67 (20) 1.17 0.74–1.83 1.00 0.63–1.59
Marital status
Never married 104 (33) 106 (32) 1 0.63 1 0.56
Currently married 162 (52) 178 (54) 0.89 0.62–1.27 0.78 0.50–1.23
Previously married¶ 47 (15) 45 (14) 1.08 0.65–1.81 0.85 0.46–1.58
Educational attainment Ptrend* 0.21
Primary (Grade 0–7) 86 (27) 94 (29) 1 0.81 1 0.62
Junior secondary (Grade 8–9) 72 (23) 81 (25) 0.99 0.64–1.55 1.13 0.71–1.80
Senior secondary (Grade 10–12) 115 (37) 114 (35) 1.12 0.74–1.71 1.32 0.83–2.10
Higher education 40 (13) 40 (12) 1.28 0.72–2.29 1.38 0.75–2.51
Employment
None 165 (53) 186 (57) 1 0.36 1 0.52
Casual/seasonal/occasional 43 (14) 44 (13) 1. 00 0.61–1.66 0.97 0.57–1.64
Self employed 49 (16) 37 (11) 1.56 0.93–2.61 1.46 0.85–2.49
Formal wage 56 (18) 62 (19) 0.97 0.63–1.51 1.00 0.63–1.60
Household conditions
SES (PCAk of HH factors and assets††)
Lower 152 (49) 170 (52) 1 0.10 1 0.15
Higher 161 (51) 159 (48) 1.36 0.94–1.96 1.31 0.90–1.89
Number of other HH members present when CHiP offered HBT Ptrend* 0.47
0 113 (37) 122 (38) 1 0.90 1 0.73
1 83 (27) 87 (27) 0.93 0.62–1.42 0.98 0.64–1.49
≥2 107 (35) 112 (35) 0.91 0.60–1.37 0.85 0.56–1.30
Was partner present when participant offered CHiP HBT?
N 237 (78) 249 (78) 1 0.53 1 0.47
Y 66 (22) 72 (22) 0.87 0.56–1.34 0.84 0.52–1.35
Lifestyle, behavioural and health factors Years lived in the community
≤3 33 (11) 63 (19) 1 0.002 1 0.003
≥4 278 (89) 261 (81) 2.09 1.31–3.32 2.01 1.25–3.22
Any nights spent away from home in last 3 m
N 159 (58) 155 (52) 1 0.19 1 0.17
Y 117 (42) 144 (48) 0.79 0.55–1.13 0.77 0.54–1.19
Number of partners in last 12 m
0 64 (23) 70 (23) 1 0.87 1 0.79
1 185 (65) 204 (67) 0.92 0.61–1.38 0.94 0.62–1.43
≥2 35 (12) 31 (10) 1.09 0.59–2.01 1.15 0.61–1.43
Audit score
Audit score ≤7 242 (77) 260 (79) 1 0.74 1 0.56
Audit score ≥8 71 (23) 69 (21) 1.07 0.71–1.61 1.13 0.75–1.72
Unwell in last 12 m
N 208 (67) 224 (68) 1 0.74 1 0.59
Y 104 (33) 105 (32) 1.06 0.75–1.50 1. 10 0.77–1.58
6 © 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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95% CI: 1.08–2.67, P = 0.02) were more likely to
decline HB-HCT.
In contrast, other factors such as thinking that HIV
is common or concerns about confidentiality of HIV
testing in the household, that might have influenced
uptake of testing, were not found to be associated
with acceptance (Table 3). There were no important
differences between cases and controls in stigmatising
attitudes that may affect uptake of HB-HTC
(Table 3).
Differences in association by gender and country
There were few differences observed when stratifying
associations by gender and country (Table S1a,b). Men
who stated that they feared an HIV-positive test result
were more likely to have declined HB-HTC (AOR: 2.68,
95% CI: 1.33–5.38, P = 0.005), whereas no such associa-
tion was noted among women (AOR: 0.84, 95% CI:
0.39–1.80, P = 0.65) (LRT for interaction with gender
P-value = 0.005).
Discussion
Our study provides evidence from large urban communi-
ties that were targeted to receive universal testing (and in
Arm A communities, universal treatment as well) (Fig-
ure 1). UTT has the potential to influence acceptability
and uptake of HIV testing and only one other quantita-
tive study to our knowledge has reported findings on pre-
dictors of uptake from a setting providing UTT. This
study was on data from a much smaller trial than
PopART, set in rural South Africa with 10 clusters and
an average population size of approximately 1000 indi-
viduals/cluster), and only a few potential factors associ-
ated with the uptake of HB-HTC were described [17.]
While there are descriptive studies of acceptors of testing
and HB-HTC, relatively few studies have directly com-
pared acceptors with non-acceptors of HB-HTC, and in-
depth quantitative data on reasons to decline are limited
[17–20]. HB-HTC acceptance has been shown to be asso-
ciated with age (>25 years) and female gender in Kenya
[18], and low socio-economic position in a the setting of
a small island in Lake Malawi [19]. Other data have
shown no association between HB-HCT uptake and
demographic or socio-economic position [17]. Prior
knowledge of HIV status (known HIV-infected or believ-
ing oneself to be uninfected based on a previous HIV-
negative test result) and not being ready to find out have
been found as reasons to decline HB-HTC in rural South
Africa [20]. Others have reported little that is signifi-
cantly different between those who accepted and those
who did not accept HB-HTC [17].
Our study sample was frequency-matched by gender
and community to ensure adequate representation of
those groups. As such, rather than identify whether there
were any differences in uptake by gender (other PopART
data on uptake of HB-HCT answer that [21]), we were
able to explore differences between those who declined
and those who accepted HB-HTC after accounting for
gender. We were also able to examine whether associa-
tions differed by the gender of the participant.
From our study within 13 large urban communities in
Zambia and South Africa, we found that among those
who were encountered and offered HB-HTC, there were
no fundamental differences based on demographic,
Table 1 (Continued)
Cases
(non-acceptors)
n (%)
Controls
(acceptors)
n (%)
Odds
ratio†
LRT‡ P-value,
95% confidence
interval
Adjusted
odds ratio§
LRT‡ P-value, 95%
confidence
interval
Any form of violence (verbal/physical/sexual) from any partner in last 12 m (among women)
No 119 (74) 130 (73) 1 0.82 1 0.90
At least once 41 (26) 49 (27) 0.94 0.56–1.57 0.98 0.57–1.67
*P-value for test for trend are in italics.
†A priori adjusted for gender and community to reflect sampling strategy.
‡Likelihood ratio test.
§Multivariable model including gender, community, age category and years lived in the community.
¶Previously married = separated/divorced/widowed.
kPrincipal components analysis.
††HH factors detailed house structure, water, sanitation, electricity and cooking fuel used; assets listed were as follows: working cell
phone, bicycle, motorcycle or scooter, car/bakkie, electricity to house, television set, fridge/freezer, radio, computer/laptop, CD or MP3
player, stereo/cassette/other music player, ‘none of the above’.
Bold font indicates findings which are statistically significant but could be shown in normal font if preferred.
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lifestyle, behavioural or health characteristics, between
those who accepted (controls) and those who declined
HB-HCT (cases). Our data indicate that there were no
specific subsets of the population who were systematically
less likely to accept testing, once contacted, suggesting
that HB-HTC has the potential to be universally accept-
able to those offered it. Evidence indicates that there are
fewer men found at home than women and HB-HTC
providers may therefore encounter less men [17, 21]. To
achieve universal coverage, innovative means must be
explored to ensure everyone in the community (or as high
a proportion as possible) is contacted so that they can be
offered HB-HTC [22].
Cases and controls did seem to differ in perceptions
held about issues related to HIV and HIV services. Most
participants gave favourable responses regarding HIV ser-
vices, and those who held positive views about the CHiPs
were less likely to have declined HB-HTC. There were
several factors that encouraged testing at the individual
level. Participants who had not tested for HIV previously
were more likely to accept HB-HTC in contrast to those
who had previously tested HIV negative or had tested
recently and felt that repeat testing was not warranted.
Participants who declined HB-HCT were less positive
about treatment for HIV than those who accepted. Fur-
ther, those who declined were more likely to hold the
view that they were not at risk of HIV and it was there-
fore not a reason for them to test. Low-risk perception as
a reason not to test was also observed by Naik et al [20.]
Yet when we explored self-reported sexual behaviour of
participants, there is no evidence that those who declined
HB-HCT were at lower risk based on the number of
partners in the last 12 months (Table 1), number of life-
time partners or age at sexual debut (data not shown).
Other views that might have been assumed to encour-
age or discourage testing had no association with
Table 2 Participants’ perceptions of HIV service factors affecting uptake of testing
Cases
(non-acceptors)
n (%)
Controls
(acceptors)
n (%)
Odds
ratio†
LRT‡ P-value,
95% confidence
interval
Adjusted
odds
ratio§
LRT‡ P-value, 95%
confidence interval
HIV service factors affecting uptake of testing
Was the CHiP known to the participant prior to offer of HBT?
N 265 (85) 272 (83) 1 0.61 1 0.49
Y 48 (15) 57 (17) 0.88 0.56–1.40 0.85 0.54–1.35
Do you think confidentiality will be maintained by the CHiP?¶ ptrend* 0.16
Strongly disagree/disagree 15 (5) 18 (5) 1 0.10 1 0.16
Agree 98 (31) 82 (25) 1.49 0.69–3.22 1.42 0.65–3.10
Strongly agree 200 (64) 229 (70) 0.95 0.46–2.00 0.91 0.43–1.94
Was the CHiP someone you could talk to openly?¶ ptrend * 0.003
Strongly disagree/disagree 12 (4) 7 (2) 1 0.002 1 0.001
Agree 92 (29) 70 (21) 0.81 0.29–2.24 0.70 0.25–1.94
Strongly agree 209 (67) 252 (77) 0.40 0.15–1.07 0.34 0.12–0.91
Providing treatment for as many HIV infected people as possible can help reduce new HIV infections
happening in your community¶
ptrend * 0.03
Strongly disagree 19 (6) 21 (6) 1 0.09 1 0.04
Disagree 46 (15) 31 (9) 1.54 0.70–3.38 1.63 0.73–3.65
Agree 91 (29) 89 (27) 1.14 0.55–2.35 1.11 0.54–2.31
Strongly agree 156 (50) 188 (57) 0.82 0.42–1.61 0.78 0.39–1.52
Group counselling for HH members (including offer of HIV test) in the home is acceptable ¶ ptrend* 0.93
Strongly disagree 41 (13) 43 (13) 1 0.80 1 0.80
Disagree 31 (10) 34 (10) 1.02 0.53–1.98 0.97 0.50–1.93
Agree 86 (28) 83 (25) 1.20 0.68–2.13 1.21 0.68–2.16
Strongly agree 154 (49) 169 (51) 0.97 0.58–1.61 0.98 0.58–1.63
*P-value for test for trend are in italics.
†A priori adjusted for gender and community to reflect sampling strategy.
‡Likelihood ratio test.
§Multivariable model including gender, community, age category and years lived in the community.
¶There were very few responses in the ‘strongly disagree’ and ‘disagree’ categories for these questions, and responses are therefore
grouped as shown to be more meaningful/increase power.
Bold font indicates findings which are statistically significant but could be shown in normal font if preferred.
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Table 3 Participants’ perceptions of advantages and disadvantages of accepting of HB-HTC
Cases
(non-acceptors)
n (%)
Controls
(acceptors)
n (%)
Odds
ratio†
LRT‡ P-value,
95% confidence
interval
Adjusted
odds ratio§
LRT‡ P-value,
95% confidence
interval
Individual level factors encouraging testing
When offered a test by the PopART CHiP, did any of the following encourage you towards having an HIV test?
I have never had an HIV test and wanted to learn my status
N 247 (79) 237 (72) 1 0.03 1 0.03
Y 65 (21) 92 (28) 0.65 0.44–0.96 0.64 0.43–0.95
HIV is common in this community so I thought I should test to check my status
N 217 (70) 223 (68) 1 0.46 1 0.37
Y 95 (30) 106 (32) 0.87 0.60–1.27 0.84 0.57–1.23
Convenience of having an HIV test at home encouraged me to test
N 164 (53) 104 (32) 1 <0.001 1 0.001
Y 148 (47) 225 (68) 0.39 0.28–0.55 0.38 0.27–0.54
Many people I know had tested with a CHiP so I wanted to as well
N 263 (84) 246 (75) 1 0.001 1 0.002
Y 49 (16) 83 (25) 0.49 0.32–0.77 0.49 0.31–0.77
Accepted CHiP advice that it was a good idea to test
N 154 (49) 89 (27) 1 <0.001 1 <0.001
Y 158 (51) 240 (73) 0.35 0.24–0.49 0.33 0.23–0.48
Getting treatment without delay if I tested and was HIV-positive (encouraged me to test)
N 149 (48) 119 (36) 1 0.004 1 0.004
Y 163 (52) 210 (64) 0.61 0.44–0.86 0.60 0.43–0.85
My sexual behaviour has put me at risk of HIV
N 263 (84) 257 (78) 1 0.02 1 0.02
Y 49 (16) 72 (22) 0.61 0.40–0.94 0.61 0.39–0.93
Individual level factors discouraging testing
When offered a test by the PopART CHiP, did any of the following discourage you from having an HIV test?
I had difficulty with the time it would take - because of my livelihood/job
N 226 (72) 247 (75) 1 0.42 1 0.52
Y 86 (28) 82 (25) 1.18 0.79–1.75 1.14 0.76–1.71
I was worried someone
would find out
I was having an HIV test
N 305 (98) 313 (95) 1 0.08 1 0.11
Y 7 (2) 16 (5) 0.45 0.18–1.12 0.48 0.19–1.22
I did not want to find out my HIV status because I was afraid of a positive test result
N 263 (84) 288 (88) 1 0.19 1 0.09
Y 49 (16) 41 (12) 1.38 0.85–2.22 1.53 0.94–2.50
I was confident I was HIV-negative and didn’t need to test
N 242 (78) 274 (83) 1 0.05 1 0.03
Y 70 (22) 55 (17) 1.53 1.00–2.34 1.61 1.04–2.51
I already had a test recently and did not want to test again
N 254 (81) 287 (87) 1 0.03 1 0.02
Y 58 (19) 42 (13) 1.63 1.05–2.53 1.69 1.08–2.67
I am not ready to find out my HIV status
N 267 (86) 289 (88) 1 0.15 1 0.12
Y 45 (14) 40 (12) 1. 50 0.86–2.64 1.57 0.88–2.77
I just did not want to find out my HIV status (no particular reason)
N 279 (89) 298 (91) 1 0.40 1 0.40
Y 33 (11) 31 (9) 1.32 0.70–2.48 1.32 0.69–2.50
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observed acceptance of HB-HTC. For example, concerns
about confidentiality with testing in the home, or the
presence of other household members during delivery of
HB-HTC (including partner), were not associated with
acceptance and so these factors did not appear to inhibit
testing. Contrary to other studies [20], ‘not feeling ready
to find out’ his/her HIV status was not found to be asso-
ciated with acceptance in our study. Having stigmatising
attitudes about HB-HTC was also not seen to be an
important barrier to uptake in our setting.
We found surprisingly few differences between
responses given by men and women. However, the data
do suggest that among men, fear of an HIV-positive
result was associated with HB-HTC non-acceptance.
Further research is needed to explain some study find-
ings, including the association of longer duration lived in
the community with non-acceptance, or the finding that
greater mobility is associated with increased likelihood of
acceptance in Zambia. Several of the communities studied
have been exposed to HTC campaigns in the past. Indi-
viduals who have been resident for longer periods may
have been tested before and therefore declined HB-HTC
when offered by PopART CHiPs. In contrast, mobility is
associated with higher sexual risk [23] and individuals
who are mobile may be more inclined to accept HB-HTC
if they feel at risk of HIV. Social science research is being
conducted on a subset of the participants from this case–
control study and in-depth interviews may provide more
nuanced explanations. There are other components of the
trial which are using qualitative methods of research
which may help provide more nuanced explanations con-
cerning the effects of mobility and permanence in the
community on uptake of HB-HTC.
Our study had some limitations to consider. To com-
ply with ethical principles and good research practice,
only individuals who were encountered and agreed to
participate in the PopART intervention, and who were
recontacted and provided informed consent for the CC
study, could be recruited as participants. Due to high
mobility in the study communities, randomly selected
individuals from the CHiP database were often difficult
to trace, to ask permission for contact by the research
team. As such, it may be that the study sample is not
fully representative of all community members and our
Table 3 (Continued)
Cases
(non-acceptors)
n (%)
Controls
(acceptors)
n (%)
Odds
ratio†
LRT‡ P-value,
95% confidence
interval
Adjusted
odds ratio§
LRT‡ P-value,
95% confidence
interval
Stigmatising attitudes which may affect uptake of testing
People are hesitant to take an HIV test due to fear of other people’s reaction if the test result is positive for HIV Ptrend * 0.18
Strongly disagree 69 (22) 72 (22) 1 0.10 1 0.10
Disagree 54 (17) 49 (15) 1.03 0.57–1.86 0.96 0.52–1.76
Agree 99 (32) 116 (35) 1.28 0.77–2.13 1.20 0.71–2.02
Strongly agree 90 (29) 92 (28) 0.73 0.45–1.18 0.68 0.42–1.12
People sometimes talk badly about people who have had or who are thought to have had an HIV test Ptrend * 0.79
Strongly disagree 69 (22) 72 (22) 1 0.78 1 0.83
Disagree 54 (17) 49 (15) 1.10 0.64–1.87 0.99 0.58–1.71
Agree 99 (32) 116 (35) 0.86 0.53–1.39 0.83 0.51–1.35
Strongly agree 90 (29) 92 (28) 1.02 0.62–1.67 0.98 0.59–1.62
People may think that I have been immoral/irresponsible as the reason behind having an HIV test Ptrend * 0.53
Strongly disagree 129 (41) 146 (44) 1 0.60 1 0.53
Disagree 69 (22) 77 (23) 0.96 0.62–1.48 0.90 0.57–1.40
Agree 68 (22) 60 (18) 1.34 0.82–2.21 1.33 0.80–2.20
Strongly agree 46 (15) 46 (14) 1.05 0.62–1.79 1.04 0.60–1.79
People receive verbal abuse or insults because of having an HIV test Ptrend * 0.90
Strongly disagree 43 (14) 44 (13) 1 0.61 1 0.82
Disagree 73 (23) 84 (26) 1.33 0.85–2.06 1.21 0.77–1.90
Agree 78 (25) 65 (20) 1.03 0.65–1.62 1.02 0.64–1.62
Strongly agree 118 (38) 136 (41) 1.04 0.61–1.77 0.97 0.56–1.69
*P-value for test for trend are in italics.
†A priori adjusted for gender and community to reflect sampling strategy.
‡Likelihood ratio test.
§Multivariable model including gender, community, age category and years lived in the community.
Bold font indicates findings which are statistically significant but could be shown in normal font if preferred.
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results should be interpreted in the light of this limita-
tion. However, the response rates in cases and controls
were very similar (as seen in Figure 2a,b) indicating
that any selection bias was likely non-differential, so
that comparisons between cases and controls should be
valid.
Finally, in common with most research using self-
reported data, reporting bias is possible. Social desirability
may have played a part in the responses given, although we
would not expect this to be differential based on whether an
individual had accepted HB-HTC for most themes studied.
We also minimised observer bias by keeping research assis-
tants unaware of case–control status of participants until
the end of the questionnaire.
However, our study also had several strengths. There
was no single or obvious hypothesis being tested, so
respondents were unlikely to give responses in order to
conform to (or contradict) such a hypothesis. In contrast
to much of the existing literature on acceptability of HIV
testing, our study is specific to the context of attempting
to provide universal testing and at large scale. Further,
we directly compared those who accepted HB-HTC with
those who did not to provide evidence of differences
rather than simply describing individuals without com-
parators. Also, by frequency matching our study sample
by gender, we ensured an adequate sample of men who
are often under-represented in studies of HIV test uptake
despite (or because of) the fact that they are more fre-
quently non-engagers with HIV services. Finally, the
study covered an extensive range of themes. The null
findings make an important contribution to identifying
which areas may be less important when designing public
health information to encourage HB-HCT.
While firm evidence of causality cannot be inferred from
this observational study, our study findings provide oppor-
tunities for tailoring services and public health messaging
to extend the reach of HB-HTC, to those who may cur-
rently be avoiding it. Our first key recommendation is with
regard to decision-making about testing being based on
whether one needs a test. We found that those who had
previously tested HIV negative or had tested recently felt
that repeat testing was not warranted. Also, participants
who indicated that their sexual behaviour put them at risk
of HIV were less likely to have declined HB-HTC. We rec-
ommend that service providers reinforce the importance of
testing irrespective of self-held perceptions of risk of HIV,
especially where universal knowledge of HIV status is
sought. WHO guidelines do not recommend retesting to
cover a ‘window-period’ [24] and it is reasonable not to
retest following a test in the last 3 months. However, if
there is any potential for ongoing exposure, repeat and
ongoing testing (e.g. annually) should be encouraged from
a public health point of view. The failure to retest because
of a past HIV-negative result may be complacent, espe-
cially in high-prevalence settings. Data from PopART
intervention delivery indicate high acceptability of HB-
HTC provided by CHiPs [25]. Data from this study which
indicate that those who held positive views about the
CHiPs were less likely to have declined HB-HTC highlight
the benefits to be gained by maximising the acceptability of
the cadre of staff delivering HB-HTC, which may help us
improve uptake and reach universality. Similarly, promot-
ing the benefits of treatment may have benefits for uptake
of testing. Among men, fear of HIV was found to influence
test uptake and efforts must be made to understand and
mitigate it. We recommend that there should be investment
in health promotion which demystifies HIV – through
expansion of channels to target men (health promotion
aligned with sporting events and activities, or tailored
male-friendly services, for instance).
Conclusion
This case–control study, which is nested within the lar-
gest HIV prevention trial to date, provides valuable
insights into the acceptability of HB-HTC. We found that
that there were no differences in uptake of HB-HTC by
demographic and behavioural characteristics suggesting
that HB-HTC has the potential to be universally accept-
able – to those who can be contacted and offered it –
although to achieve universal coverage, innovative ways
to make contact and offer HB-HTC extensively will be
needed. Ideally, a mixture of approaches (including
stand-alone, health facility, community location and
home-based methods) should be made available, so that
individuals have a choice and coverage may be max-
imised. We have identified perceptions and opinions held
by community members that could help tailor public
health messaging with a view to achieving universal
knowledge of HIV status in high-prevalence settings.
Acknowledgements
We are grateful to study participants and members of the
communities where the study was conducted. We would
like to acknowledge the involvement of various teams
within PopART, especially CHiPs, data management and
social science colleagues, as well as the specific input
from the PopART Principal Investigator in South Africa –
Nulda Beyers. HPTN 071 is sponsored by the National
Institute of Allergy and Infectious Diseases (NIAID)
under Cooperative Agreements UM1-AI068619, UM1-
AI068617 and UM1-AI068613, with funding from the
© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 11
Tropical Medicine and International Health volume 00 no 00
K. Sabapathy et al. Acceptability of home-based HIV testing in the HPTN 071 (PopART) trial
U.S. President’s Emergency Plan for AIDS Relief (PEP-
FAR). Additional funding is provided by the International
Initiative for Impact Evaluation (3ie) with support from
the Bill & Melinda Gates Foundation, as well as by
NIAID, the National Institute on Drug Abuse (NIDA)
and the National Institute of Mental Health (NIMH), all
part of NIH. The content is solely the responsibility of
the authors and does not necessarily represent the official
views of the NIAID, NIMH, NIDA, PEPFAR, 3ie or the
Bill & Melinda Gates Foundation.
References
1. UNAIDS. Fast-track: Ending the AIDS Epidemic by 2030.
(Available from: http://wwwunaidsorg/sites/default/files/med
ia_asset/JC2686_WAD2014report_enpdf) 2015 [28 May
2015]
2. UNAIDS. 90-90-90 On the right track towards the global
target. (Available from: http://wwwcfenetubcca/sites/defa
ult/files/uploads/IAS2016/90_90_90_Progress_ReportFI
NALpdf) 2016 [27 July 2016]
3. Cohen M, Chen Y, McCauley M. Final results of the HPTN
052 randomized controlled trial: antiretroviral therapy pre-
vents HIV transmission. 8th International AIDS Society
Conference on HIV Pathogenesis, Treatment and Prevention,
Vancouver. 2015; Oral Presentation (Abstract
MOAC0101LB).
4. Cohen MS, Chen YQ, McCauley M et al. Prevention of
HIV-1 infection with early antiretroviral therapy. N Engl J
Med 2011: 365: 493–505.
5. INSIGHT START Study Group. Initiation of antiretroviral
therapy in early asymptomatic HIV infection. N Engl J Med
2015: 373: 795–807.
6. TEMPRANO ANRS Study Group. A trial of early antiretro-
virals and isoniazid preventive therapy in Africa. N Engl J
Med 2015: 373: 808–822.
7. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG.
Universal voluntary HIV testing with immediate antiretrovi-
ral therapy as a strategy for elimination of HIV transmis-
sion: a mathematical model. Lancet 2009: 373: 48–57.
8. BCPP Study Group. Botswana Combination Prevention Pro-
ject (BCPP). (Available from: https://clinicaltrialsgov/ct2/
show/NCT01965470) 2013 [26 Nov 2015]
9. Hayes R, Ayles H, Beyers N et al. HPTN 071 (PopART):
rationale and design of a cluster-randomised trial of the
population impact of an HIV combination prevention inter-
vention including universal testing and treatment - a study
protocol for a cluster randomised trial. Trials 2014: 15: 57.
10. SEARCH Study Team. Sustainable East Africa Research in
Community Health (SEARCH). (Available from: https://clini
caltrialsgov/ct2/show/NCT01864603?term=
NCT01864603&rank=1) 2013 [26 Nov 2015]
11. The MaxART Programme. (Available from: http://stopaids
noworg/treatment-prevention) 2011 [20 July 2016]
12. Cori A, Ayles H, Beyers N et al. HPTN 071 (PopART): a
cluster-randomized trial of the population impact of an HIV
combination prevention intervention including universal test-
ing and treatment: mathematical model. PLoS ONE 2014:
9: e84511.
13. Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N.
Uptake of home-based voluntary HIV testing in sub-Saharan
Africa: a systematic review and meta-analysis. PLoS Med
2012: 9: e1001351.
14. Sharma M, Ying R, Tarr G, Barnabas R. Systematic review
and meta-analysis of community and facility-based HIV test-
ing to address linkage to care gaps in sub-Saharan Africa.
Nature 2015: 528: S77–S85.
15. Suthar AB, Ford N, Bachanas PJ et al. Towards universal
voluntary HIV testing and counselling: a systematic review
and meta-analysis of community-based approaches. PLoS
Med 2013: 10: e1001496.
16. Iwuji C, Orne-Gliemann J, Balestre E et al. The impact of
universal test and treat on HIV incidence in a rural South
African population: ANRS 12249 TasP trial, 2012–2016.
21st International AIDS Conference, Durban. 2016;abstract
FRAC0105LB.
17. Iwuji CC, Orne-Gliemann J, Larmarange J et al.Uptake of
home-based HIV testing, linkage to care, and community atti-
tudes about ART in rural KwaZulu-Natal, South Africa:
descriptive results from the first phase of the ANRS 12249
TasP cluster-randomised trial. PLoSMed 2016: 13: e1002107.
18. Lugada E, Levin J, Abang B et al. Comparison of home and
clinic-based HIV testing among household members of per-
sons taking antiretroviral therapy in Uganda: results from a
randomized trial. J Acquir Immune Defic Syndr 2010: 55:
245–252.
19. Helleringer S, Kohler HP, Frimpong JA, Mkandawire J.
Increasing uptake of HIV testing and counseling among the
poorest in sub-Saharan countries through home-based service
provision. J Acquir Immune Defic Syndr 2009: 51: 185–193.
20. Naik R, Tabana H, Doherty T, Zembe W, Jackson D. Client
characteristics and acceptability of a home-based HIV coun-
selling and testing intervention in rural South Africa. BMC
Public Health 2012: 12: 824.
21. Hayes R, Floyd S, Schaap A et al. A universal testing and
treatment intervention to improve HIV control: one-year
results from intervention communities in Zambia in the
HPTN 071 (PopART) cluster-randomised trial. PLoS Med
2017: 14: e1002292.
22. Yang B, van Deventer D, Dunbar R et al. Working evening
and weekend schedules is effective in reaching more men for
home-based HIV testing: findings from HPTN 071
(PopART) in South Africa. 21st International AIDS Confer-
ence, Durban. 2016.
23. Weine SM, Kashuba AB. Labor migration and HIV risk: a
systematic review of the literature. AIDS Behav 2012: 16:
1605–1621.
24. World Health Organization. Consolidated guidelines on
HIV testing services. (Available from: http://appswhoint/iris/
12 © 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 00 no 00
K. Sabapathy et al. Acceptability of home-based HIV testing in the HPTN 071 (PopART) trial
bitstream/10665/179870/1/9789241508926_engpdf?ua=
1&ua=1) 2015 [26 July 2016]
25. Hayes R, HPTN 071 (PopART) Study Team. Reaching
the 90-90-90 target: Lessons from HPTN 071 (PopART).
(Available from: http://wwwtreatmentaspreventionwork
shoporg/un-90-90-90-target-workshop-videos) Interna-
tional Treatment as Prevention Workshop, 2015 [4 Nov
2016]
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1 (a) Factors with effect modification by gen-
der, of association with case/control status. (b) Factors
with effect modification by country, of association with
case/control status.
Corresponding Author Kalpana Sabapathy, LSHTM, Keppel Street, London WC1E 7HT, UK. Tel.:+44 207 927 2155; E-mail:
kalpana.sabapathy@lshtm.ac.uk
© 2018 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 13
Tropical Medicine and International Health volume 00 no 00
K. Sabapathy et al. Acceptability of home-based HIV testing in the HPTN 071 (PopART) trial
